国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01099 国药控股

未开盘 06-10 16:09:07

17.080

+0.190

+1.12%

最高17.120	最低16.810	成交量597.35万
今开16.890	昨收16.890	日振幅1.84%
总市值533.07亿	流通市值229.18亿	总股本31.21亿
成交额1.02亿	换手率0.45%	流通股本13.42亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01099","market":"HK","secType":"STK","nameCN":"国药控股","latestPrice":17.08,"timestamp":1781078947003,"preClose":16.89,"halted":0,"volume":5973509,"delay":0,"changeRate":0.011249259917110581,"floatShares":1341810740,"shares":3121000000,"eps":2.29,"marketStatus":"未开盘","change":0.19,"latestTime":"06-10 16:09:07","open":16.89,"high":17.12,"low":16.81,"amount":101589261,"amplitude":0.018354,"askPrice":17.08,"askSize":121200,"bidPrice":17.01,"bidSize":41200,"shortable":3,"etf":0,"ttmEps":2.578586,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781141400000},"marketStatusCode":0,"adr":0,"listingDate":1253635200000,"exchange":"SEHK","adjPreClose":16.89,"dividendRate":0.046713,"openAndCloseTimeList":[[1781055000000,1781064000000],[1781067600000,1781078400000]],"volumeRatio":0.9216701727448976,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SNP.HK","impliedVol":0.3003,"impliedVolPercentile":0.7236},"requestUrl":"/m/hq/s/01099/tweets","defaultTab":"tweets","newsList":[{"id":"1143121858","title":"贝莱德增持国药控股H股，持股比例从8.74%升至9.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143121858","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143121858?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:17","pubTimestamp":1780996647,"startTime":"0","endTime":"0","summary":"根据香港交易所披露的最新权益信息，全球资管巨头贝莱德对国药控股H股的持股比例出现显著提升。截至6月3日，贝莱德持有的国药控股H股好仓权益比例已增至9.84%，相较于此前披露的8.74%增加了1.1个百分点。贝莱德此番增持，不仅增强了其在该公司的话语权，也可能对其他投资者的决策产生一定的引导效应。后续，市场将密切关注国药控股的经营表现以及主要股东持股结构的进一步变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640798160.USD","01099","BK1197","LU1115378108.SGD","BK1515","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640870152","title":"中信证券资管公司减持国药控股(01099)177.52万股 每股均价约16.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640870152","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640870152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:29","pubTimestamp":1780572543,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月1日，中信证券资产管理有限公司减持国药控股(01099)177.52万股，每股均价16.9396港元，总金额约为3007.12万港元。减持后最新持股数目约为1.46亿股，最新持股比例为10.87%。本次交易涉及其他关联方：中信证券-云帆单一资产管理计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","LU1720050803.USD","BK0012","LU0405327494.USD","LU1115378108.SGD","600030","LU2289578879.USD","LU1064131003.USD","BK1197","LU2148510915.USD","EWH","LU1255011170.USD","LU1997244956.HKD","BK1500","BK0183","LU1997245094.SGD","BK1515","LU0640798160.USD","BK1564","BK0196","BK0188","BK1516","LU1064130708.USD","06030","LU1781817850.SGD","LU1580142542.USD","BK0028","LU1794554557.SGD","BK0276","LU2495084118.USD","LU1655091616.SGD","LU1328615791.USD","BK1147","BK1521","LU0405327148.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150690614","title":"国药控股5月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150690614","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150690614?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:36","pubTimestamp":1780562204,"startTime":"0","endTime":"0","summary":"2026年6月4日，国药控股发布2026年5月股份变动月报表。公告显示，公司法定/注册股本为人民币3,120,656,191元，截至5月31日未发生任何增减变动。公司目前的H股为1,341,810,740股，内资股为1,778,845,451股，面值均为1元人民币。报告期内，公司无新增发行、购回、注销或库藏股行为，已发行股份总数较上月底维持不变。公司方面进一步表示，将继续遵守相关上市规则及法律法规的规定，维持股本结构的稳定性和合规性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693461","title":"FMR LLC减持国药控股(01099)约594.78万股 每股作价约17.69港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693461","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638693461?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:26","pubTimestamp":1779971170,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月22日，FMR LLC减持国药控股(01099)594.7847万股，每股作价17.6879港元，总金额约为1.05亿港元。减持后最新持股数目约为1.06亿股，最新持股比例为7.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","LU0640798160.USD","LU1115378108.SGD","BK1197","01099","BK1515","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123457668","title":"国药控股拟回购不超过已发行H股总额10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123457668","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123457668?lang=zh_cn&edition=full","pubTime":"2026-05-28 06:11","pubTimestamp":1779919895,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司近日在公告中披露，公司董事会拟取得一般授权，以在2026年股东周年大会及相关类别股东大会批准后，于授权有效期间回购不超过公司已发行H股总数10%的股份。根据公告，截至2026年5月22日，公司已发行H股约为13.42亿股，若全部行使，该计划的最大回购规模约为1.34亿股。根据公告，股东大会及相关类别股东大会拟于2026年6月18日举行，凡于6月15日名列公司股东名册的股东均有权出席并表决。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药控股拟回购不超过已发行H股总额10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638593555","title":"太极集团：下属子公司重庆桐君阁股份有限公司已正式委托给国药控股股份有限公司管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2638593555","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638593555?lang=zh_cn&edition=full","pubTime":"2026-05-25 21:39","pubTimestamp":1779716340,"startTime":"0","endTime":"0","summary":"太极集团在互动平台回答投资者提问时表示，目前，公司下属子公司重庆桐君阁股份有限公司已正式委托给国药控股股份有限公司管理，相关工作均正常开展。后期公司将协同国药集团推进解决同业竞争，相关进展将严格按照《上海证券交易所股票上市规则》的要求进行信息披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253748490924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1500","LU1115378108.SGD","BK0239","LU0640798160.USD","BK1515","600129","BK1197","01099","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635408236","title":"FMR LLC减持国药控股(01099)199.76万股 每股作价18.4051港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635408236","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635408236?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:19","pubTimestamp":1778847556,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月12日，FMR LLC减持国药控股(01099)199.76万股，每股作价18.4051港元，总金额约为3676.60万港元。减持后最新持股数目约为1.20亿股，最新持股比例为8.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","LU0640798160.USD","LU1115378108.SGD","BK1197","01099","BK1515","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348767384.USD","02367","LU0561508036.HKD","BK1588","LU0634319403.HKD","LU0417516738.SGD","03933","LU1794554557.SGD","01789","LU0348783233.USD","LU1251922891.USD","HK0000165453.HKD","06821","02228","BK0188","LU0588546209.SGD","LU0417516902.SGD","BK1593","02268","LU2476274720.SGD","BK1161","LU2488822045.USD","BK1583","BK0276","LU0417516571.SGD","LU0348766576.USD","LU0640798160.USD","BK1197","09688","09926","02196","01099","06160","01530","BK1500","LU1719994722.HKD","CXO","BK1141","LU2778985437.USD","LU2328871848.SGD","LU0348735423.USD","BK1207","601881","LU1969619763.USD","BK1585","LU1303224171.USD","IE00BPRC5H50.USD","LU1961090484.USD","06881","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137936242","title":"国药控股更新2026年4月股份变动月报表，股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1137936242","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137936242?lang=zh_cn&edition=full","pubTime":"2026-05-07 06:11","pubTimestamp":1778105470,"startTime":"0","endTime":"0","summary":"国药控股股份有限公司（股票代码：01099）于2026年5月7日发布截至2026年4月30日的股份变动月报表。公告显示，公司注册股本合计人民币3,120,656,191元，当月未发生新增发行、回购或注销等变化，股本结构维持稳定。\n本次月度报告期内，国药控股H股数量为1,341,810,740股，内资股（其他类普通股）数量为1,778,845,451股，两类股份合计上月与本月底数额一致，均未发生增减变化。公司同时确认，截至2026年4月底已符合香港联交所《上市规则》所规定的公众持股量要求。\n上述公告由公司秘书吴壹建签署。公司表示将持续遵守香港联交所及相关法律法规要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132259822","title":"国药控股2026年第一季度营收178.23亿元，经调整净利润2.80亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132259822","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132259822?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:06","pubTimestamp":1777457189,"startTime":"0","endTime":"0","summary":"国药控股公布2026年第一季度财务数据显示，在报告期内实现营收178.23亿元，同比下降2.57%。同期经调整净利润为2.80亿元，同比下降11.77%。经营现金流净额为-29.35亿元，同比下降61.52%。公司表示，受行业政策调整、市场竞争加剧以及下游回款延迟等因素影响，整体业绩出现一定程度下滑。零售板块方面，实现营收47.39亿元，同比下降4.89%；净利润0.05亿元，同比增长15.42%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630719324","title":"大行评级丨高盛：下调国药控股目标价至19.07港元，预期未来数季收入将逐步复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2630719324","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630719324?lang=zh_cn&edition=full","pubTime":"2026-04-28 14:07","pubTimestamp":1777356421,"startTime":"0","endTime":"0","summary":"高盛发表研报指，国药控股2026年首季销售额约1404亿元，按年微跌0.6%，略低于该行预期，主要由于行业环境持续受压。不过收入趋势自2024年第四季起已出现企稳，该行预期未来几季将逐步复苏，预测今年第二、三、四季销售分别按年跌0.1%、增0.3%及增0.9%。毛利率进一步降至6.44%，反映带量采购(VBP)范围扩大及国家医保目录(NRDL)进一步降价的影响，部分被严格的成本控制所抵销。基于业绩表现，高盛下调国药控股2026至2028年盈利预测3.8%、4.6%及3.5%，以反映销售增长复苏较预期疲弱及对现金循环更保守的假设；目标价由19.83港元下调至19.07港元，评级“中性”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260428/32183540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01099","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630321450","title":"大行评级丨花旗：微降国药控股目标价至22.6港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2630321450","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630321450?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:47","pubTimestamp":1777355221,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，国药控股2026年首季度收入录1408亿元，按年微跌0.6%，大致符该行预期。按业务划分，管理层指出药品分销业务按年轻微下跌，而医疗器械分销业务的按年跌幅有所收窄，为该业务初步企稳的迹象。较为乐观的是，零售业务年增5%。花旗预期行业整合将持续，国药有望通过持续的城市层面网络扩张，在二三线城市获得市场份额。于药品分销业务持续疲软，花旗下调国药2026至2028年收入预测2%、2%及3%，相应下调同期净利润预测1%、1%及1%，目标价由22.8港元微降至22.6港元，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260428/32183469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01099","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121740234","title":"异动解读 | 国药控股盘中大跌5.05%，一季度净利润同比下滑近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121740234","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121740234?lang=zh_cn&edition=full","pubTime":"2026-04-27 14:49","pubTimestamp":1777272550,"startTime":"0","endTime":"0","summary":"国药控股今日盘中股价大幅下挫，跌幅达5.05%，引起市场关注。消息面上，公司于今日盘前发布了截至2026年3月31日的第一季度业绩报告。数据显示，公司营业总收入为1407.66亿元人民币，同比微降0.63%；归属于母公司所有者的净利润为14.14亿元人民币，同比减少2.95%，业绩表现承压。国药一致一季度归母净利润同比减少12.36%；国药器械的营业利润同比大幅下滑20.41%。仅有国药股份实现了营收和净利润的同比增长，表现相对稳健。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630193332","title":"国药控股(01099)一季度归母净利润14.14亿元 同比减少2.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630193332","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630193332?lang=zh_cn&edition=full","pubTime":"2026-04-27 07:58","pubTimestamp":1777247936,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布截至2026年3月31日止3个月季度业绩，营业总收入1407.66亿元，同比减少0.63%;归属于母公司所有者的净利润14.14亿元，同比减少2.95%;基本每股收益0.45元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110941421","title":"国药控股2026年第一季度营收1407.66亿元，净利润14.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110941421","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110941421?lang=zh_cn&edition=full","pubTime":"2026-04-27 07:42","pubTimestamp":1777246926,"startTime":"0","endTime":"0","summary":"国药控股公布的财报显示，截至2026年3月31日止三个月，集团实现营收1407.66亿元，同比下降0.63%。本期净利润14.14亿元，同比下降2.95%。期内毛利率约为6.65%，去年同期约为6.98%。经营利润率约为2.03%，上年同期为2.07%。财报中未披露具体业务板块的营收增幅及细分数据，公告主要披露了公司整体的营运表现。根据公告，营业成本的减少与销售及管理费用率的总体下降在一定程度上缓解了营收小幅下滑带来的影响；研发投入约为0.03%，相较去年同期也有所下降。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药控股2026年第一季度营收1407.66亿元，净利润14.14亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198138143","title":"国药控股2025年营收微降、母公司溢利保持增长，分销与零售业务协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1198138143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198138143?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:44","pubTimestamp":1777020250,"startTime":"0","endTime":"0","summary":"在2025年宏观环境总体稳健、医改政策和集采制度不断推进的背景下，国药控股于报告期内实现收入人民币5,751.68亿元，同比相比2024年的5,847.08亿元有所下降，降幅约1.60%。集团整体毛利为416.72亿元，毛利率由上年的7.57%微降至7.25%。总体而言，国药控股在2025年面对行业政策与市场环境变化，收入规模略有回落，但依托成熟的分销网络、零售布局及精细化管理能力，实现母公司持有者应占溢利稳步增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"国药控股2025年营收微降、母公司溢利保持增长，分销与零售业务协同推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629688943","title":"国药控股(01099)：国药器械第一季度营业利润2.2亿元 同比减少20.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629688943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629688943?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:02","pubTimestamp":1776934957,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药控股(01099)发布公司附属公司中国医疗器械有限公司(国药器械)截至2026年3月31日止3个月的财务数据。该公司取得营业收入约170亿元，同比增加1.23%;营业利润2.2亿元，同比减少20.41%;归属于母公司所有者的综合收益1.15亿元，同比减少7.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01099","LU0640798160.USD","LU1115378108.SGD","BK1515","BK1500","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144237355","title":"国药控股2026年第一财季营收170.00亿元，经调整净利润1.15亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144237355","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144237355?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:01","pubTimestamp":1776934881,"startTime":"0","endTime":"0","summary":"本季度信息\n2026年第一财季，国药控股实现营收约170.00亿元，同比增长1.23%。经调整净利润约1.15亿元，同比下降7.47%。同期经营利润约2.20亿元，同比下降20.41%。经营利润率约为1.29%。经营活动产生的现金流量净额为-45.69亿元，较上年同期增长45.86%。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126998584","title":"国药控股第一季度营收135.55亿元，经调整净利润4.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126998584","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126998584?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:12","pubTimestamp":1776859922,"startTime":"0","endTime":"0","summary":"本季度信息\n根据公告显示，国药控股(01099)2026年第一季度实现营业收入约135.55亿元，同比增长6.63%。扣除非经常性损益后，经调整净利润约为4.65亿元，同比增长4.22%。经营活动产生的现金流量净额为-35.93亿元。\n业务分项\n（该财报未披露具体业务板块营收情况。）\n高管解读\n（该财报未披露相关高管言论。）","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118912962","title":"国药控股2026年第一季度营收178.23亿元，净利润2.80亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118912962","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118912962?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:38","pubTimestamp":1776771493,"startTime":"0","endTime":"0","summary":"根据公告，2026年第一季度国药控股实现营收178.23亿元，同比下降2.57%。扣除非经常性损益后的净利润为2.80亿元，同比下降11.77%。同期营业利润为3.77亿元，同比下降14.24%。收入下滑主要受行业政策变化及市场竞争加剧等因素影响，但公司通过优化业务结构、强化亏损企业治理等措施，削减了人工及租金等刚性费用，带动整体利润降幅相对收窄。分销板块报告期内营收133.56亿元，同比下降1.72%；净利润1.99亿元，同比下降13.60%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinopharmgroup.com.cn","stockEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":-0.0733},{"period":"3month","weight":-0.189},{"period":"6month","weight":-0.1611},{"period":"1year","weight":-0.067},{"period":"ytd","weight":-0.1214}],"compareEarnings":[{"period":"1week","weight":-0.0478},{"period":"1month","weight":-0.0757},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0604},{"period":"1year","weight":0.0101},{"period":"ytd","weight":-0.0477}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"国药控股股份有限公司是一家主要从事药品、医疗保健产品及医疗器械批发和零售业务的中国公司。该公司通过四个部门运营业务。医药分销部门为国内外药品及保健品制造商及其他供货商提供分销、物流及其他加值服务。器械分销部门向客户分销医疗器材。医药零售业务部门拥有直接经营或特许经营的零售药局网路。其他业务部门从事药品、化学试剂及实验室用品的制造与销售。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.004643},{"month":2,"riseRate":0.588235,"avgChangeRate":0.029413},{"month":3,"riseRate":0.470588,"avgChangeRate":0.007007},{"month":4,"riseRate":0.411765,"avgChangeRate":0.016485},{"month":5,"riseRate":0.588235,"avgChangeRate":-0.009217},{"month":6,"riseRate":0.470588,"avgChangeRate":-0.004952},{"month":7,"riseRate":0.5,"avgChangeRate":-0.015111},{"month":8,"riseRate":0.4375,"avgChangeRate":0.012101},{"month":9,"riseRate":0.4375,"avgChangeRate":-0.011177},{"month":10,"riseRate":0.647059,"avgChangeRate":0.042295},{"month":11,"riseRate":0.470588,"avgChangeRate":-0.007287},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.004122}],"exchange":"SEHK","name":"国药控股","nameEN":"SINOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药控股,01099,国药控股股票,国药控股股票老虎,国药控股股票老虎国际,国药控股行情,国药控股股票行情,国药控股股价,国药控股股市,国药控股股票价格,国药控股股票交易,国药控股股票购买,国药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药控股(01099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药控股(01099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}